Middle East respiratory syndrome - Pipeline Insight, 2022

DelveInsight's, "Middle East Respiratory Syndrome - Pipeline Insight, 2022," report provides comprehensive insights about 12+ companies and 12+ pipeline drugs in Middle East Respiratory Syndrome pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered:

• Global coverage

Middle East Respiratory Syndrome Understanding

Middle East Respiratory Syndrome: Overview

The Middle East Respiratory Syndrome (MERS) is a lethal zoonotic severe lung infection caused by a legal pathogen Middle East Respiratory Syndrome Coronavirus (MERS-CoV). It was first identified in humans in Saudi Arabia and Jordan in 2012. Coronaviruses are large (28-32 kb) single-stranded positive-sense RNA viruses. To enter host cells, MERS-CoV attaches to its receptor, dipeptidyl peptidase 4. Symptoms include fever, cough and shortness of breath. Other symptoms include nausea, vomiting and diarrhea. Pneumonia is common, and sometimes it cause injury to organs, such as the kidneys. Protease cleavage of the S protein is then required for virus-cell fusion and release of genomic RNA into the cytoplasm. Viral RNA transcription and replication occurs on double membrane vesicles and other membranous structures, which are derived from the endoplasmic reticulum. MERS can be confirmed by detection of viral nucleic acid or by serology. The presence of viral nucleic acid can be confirmed either by positive real-time reverse transcription PCR on at least two specific genomic targets or by a single positive target with sequencing of a second positive PCR product. No specific drug treatment exists for MERS and supportive treatment is the mainstay of management.

"Middle East Respiratory Syndrome - Pipeline Insight, 2022" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Middle East Respiratory Syndrome pipeline landscape is provided which includes the disease overview and Middle East Respiratory Syndrome treatment guidelines. The assessment part of the report embraces, in depth Middle East Respiratory Syndrome commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Middle East Respiratory Syndrome collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights:

The companies and academics are working to assess challenges and seek opportunities that could influence Middle East Respiratory Syndrome R&D. The therapies under development are focused on novel approaches to treat/improve Middle East Respiratory Syndrome.

Middle East Respiratory Syndrome Emerging Drugs Chapters

This segment of the Middle East Respiratory Syndrome report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Middle East Respiratory Syndrome Emerging Drugs

INO-4700: Inovio pharmaceuticals

INO-4700 (GLS-5300) is a DNA plasmid vaccine that expresses the MERS-CoV spike (S) glycoprotein and was co-developed by GeneOne Life Science Inc. and Inovio Pharmaceuticals. The INO-4700 MERS-CoV product is a DNA vaccine candidate, allowing rapid design and production in response to emerging infectious diseases. Underscoring the potential for rapid deployment of DNA vaccines, INO-4700 was advanced into the clinic within nine months of preclinical vaccine candidate selection. INOVIO's Phase II trial is designed to evaluate INO-4700, its DNA vaccine candidate for the prevention of MERS, a disease in the coronavirus family for which there are no approved vaccines.

VTP-500: Vaccitech

VTP-500 (ChAdOx1) is a vaccine candidate in Phase I clinical trials that protects people against the Middle East Respiratory Syndrome Coronavirus (MERS-CoV) and the novel SARS-CoV-2 coronavirus. Vaccitech's VTP-500 MERS vaccine utilizes the ChAdOx1 virus platform to encode MERS coronavirus spike protein to induce T cells and antibodies that block virus-host cell receptor binding and fusion or neutralize virus infection.

Further product details are provided in the report……..

Middle East Respiratory Syndrome: Therapeutic Assessment

This segment of the report provides insights about the different Middle East Respiratory Syndrome drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Middle East Respiratory Syndrome

There are approx. 12+ key companies which are developing the therapies for Middle East Respiratory Syndrome. The companies which have their Middle East Respiratory Syndrome drug candidates in the most advanced stage, i.e. Phase II include, Inovio pharmaceuticals.

Phases

DelveInsight's report covers around 12+ products under different phases of clinical development like:

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Middle East Respiratory Syndrome pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as:

• Oral
• Parenteral
• Intravenous
• Subcutaneous
• Topical.
• Molecule Type

Products have been categorized under various Molecule types such as:

• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy
• Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Middle East Respiratory Syndrome: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Middle East Respiratory Syndrome therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Middle East Respiratory Syndrome drugs.

Middle East Respiratory Syndrome Report Insights

• Middle East Respiratory Syndrome Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Middle East Respiratory Syndrome Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Middle East Respiratory Syndrome drugs?

• How many Middle East Respiratory Syndrome drugs are developed by each company?

• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Middle East Respiratory Syndrome?

• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Middle East Respiratory Syndrome therapeutics?

• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?

• What are the clinical studies going on for Middle East Respiratory Syndrome and their status?

• What are the key designations that have been granted to the emerging drugs?

Key Players

• Neurovax
• Vaccitech
• Inovio Pharmaceuticals
• AIM Immunobiotech
• Cocrystal pharma
• Regeneron Pharmaceuticals
• Greffex
• Global BioLife Inc Ltd
• Planet Biotechnology

Key Products

• MERS vaccine
• INO-4700
• VTP-500
• Interferon alpha n3
• CDI-45205
• Research programme: DNA vaccines
• Middle East respiratory syndrome coronavirus vaccine
• DPP4-Fc